促銷價(jià):3500
品牌: ATCC細(xì)胞
貨號(hào): NK-92
生長(zhǎng)狀態(tài): 懸浮生長(zhǎng)
運(yùn)輸方式: T25瓶或干冰
器官來(lái)源: 血液系統(tǒng)
是否是腫瘤細(xì)胞: 是
細(xì)胞形態(tài): 聚團(tuán)生長(zhǎng)
物種來(lái)源: 人源
組織來(lái)源: 血液
Novagen Catlog: NGT-CRL-2407
Cell name: NK-92
ATCC Number: CRL-2407
Depositors: Conkwest Inc.
Biosafety Level: 2
Growth property: Suspension, multicell aggregates
Morphology: Lymphoblast
Species: Homo sapiens (human)
Source: Cell type: natural killer cell; NK cell
Disease: malignant non-Hodgkin's lymphoma
Antigen Expressed: CD2 +, CD7 +, CD11a +, CD28 + , CD45 +, CD54 +, CD56 +, CD1 -, CD3 -,
CD4 -, CD5 -, CD8 -, CD10 -, CD14 -, CD16 -, CD19 -, CD20 -, CD23 -, CD34 -,
HLA-DR -
Ethnic origin: Caucasian
Age: 50 years
Gender: Male
Growth medium: Alpha Minimum Essential medium without ribonucleosides and deoxyribo-nucleosides
but with 2 mM L-glutamine and 1.5 g/L sodium bicarbonate + 0.2 mM inositol + 0.1 mM 2-mercaptoethanol + 0.02 mM folic acid + 100-200 U/ml recombinant IL-2 + 12.5% horse serum + 12.5% fetal bovine serum
Temperature: 37.0℃
Subculturing: Subcultivation Ratio: 1:2 to 1:3 is recommended Subculture every 2 to 3 days
Comments: NK-92 is an interleukin-2 (IL-2) dependent Natural Killer Cell line derived from peripheral
blood mononuclear cells from a 50 year old Caucasian male with rapidly progressive non-Hodgkin's lymphoma.
The cell line is dependent on the presence of recombinant Il-2 and a dose as low as 10 U/ml is sufficient to maintain proliferation; cells will die within 72 hours in the absence of IL-2.
The cell line is cytotoxic to a wide range of malignant cells; it kills both K562 cells and Daudi cells in chromium release assays.
NK-92 cells (after irradiation to prevent proliferation) can be used effectively for immunological ex vivo purging of leukemia from blood without compromising hematopoietic cell function.
NK-92 cells have the following characteristics: surface marker positive for CD2, CD7, CD11a, CD28, CD45, CD54 and CD56 bright; surface marker negative for CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34 and HLA-DR.
Species determination: STR analysis (intraspecies) Human (Unique DNA Profile)
TH01: 6, 9.3
D5S818: 12 13
D13S317: 9, 12
D7S820: 10, 11
D16S539: 11, 12
CSF1PO: 11, 12
Amelogenin: X, Y
vWA: 18
TPOX: 8
1 March 2016 | Volume 7 | Article 91
Review
published: 14 March 2016
doi: 10.3389/fimmu.2016.00091
Frontiers in Immunology | www.frontiersin.org
1 November 2015 | Volume 6 | Article 578
Review
published: 17 November 2015
doi: 10.3389/fimmu.2015.00578
Frontiers in Immunology | www.frontiersin.org
該細(xì)胞在各大雜志上有報(bào)道,并且美國(guó)食品藥品監(jiān)督管理局(FDA)和倫理委員會(huì)(IRB)已經(jīng)批準(zhǔn)使用指定細(xì)胞庫(kù)提供的無(wú)病原體NK-92細(xì)胞,在德國(guó)進(jìn)行的臨床試驗(yàn),且報(bào)道臨床二期的數(shù)據(jù)較為理想。
本株NK-92細(xì)胞由我公司安諾倫生物于16年2月引進(jìn),傳代清晰,已做STR基因分型鑒定報(bào)告,并為該株細(xì)胞配套專用NK92無(wú)血清培養(yǎng)體系,使得這株細(xì)胞培養(yǎng)更為容易。
官方網(wǎng)站:www.ebioshop.cn
官方微信: 微信公眾平臺(tái)搜索 “安諾倫生物”
咨詢郵箱: inquiry@annoron.com
序號(hào) | 最新資訊 | 瀏覽次數(shù) | 作者 | 發(fā)布時(shí)間 |
1 | 安諾倫授權(quán)全國(guó)代理Gentarget Inc品牌產(chǎn)品 | 331 | 市場(chǎng)部 | 2023-01-30 |
2 | 安諾倫生物全國(guó)授權(quán)代理Eaglebio品牌產(chǎn)品 | 362 | 市場(chǎng)部 | 2023-01-06 |
3 | 安諾倫全國(guó)授權(quán)代理Sterlitech品牌產(chǎn)品 | 1243 | 市場(chǎng)部 | 2022-12-28 |
4 | 安諾倫銷售Agrisera品牌產(chǎn)品——植物抗體領(lǐng)航者 | 1946 | 市場(chǎng)部 | 2021-11-30 |
5 | 安諾倫代理BioVendor品牌價(jià)格優(yōu)品質(zhì)有保障 | 1414 | 市場(chǎng)部 | 2021-11-04 |
6 | 兔子單克隆抗體制備 | 1541 | 市場(chǎng)部 | 2021-11-04 |